Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.7700 (-2.45%) ($5.7700 - $5.7700) on Thu. Feb. 18, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.5% (three month average) | RSI | 58 | Latest Price | $5.7700(-2.45%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.5% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) FXI(15%) MCHI(11%) TLT(8%) VWO(8%) VXX(7%) | Factors Impacting ADMS price | ADMS will decline at least -2.25% in a week (0% probabilities). JETS(-26%) VCSH(-20%) CEMB(-18%) XLY(-14%) REMX(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.25% (StdDev 4.5%) | Hourly BBV | -0.6 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.95(-3.03%) | 10 Day Moving Average | $6.04(-4.47%) | 20 Day Moving Average | $5.77(0%) | To recent high | -13.4% | To recent low | 15.4% | Market Cap | $163m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |